Mosquitoes and other insects transmit many important viral pathogens. Some of these arthropod-borne (arbo-)viruses are responsible for worldwide epidemics and high mortality rates. For example, Dengue virus, a positive-sense (+) RNA virus from the Flavivirus family, causes an estimated 50-100 million infections per year worldwide and can causes severe, sometimes fatal disease. Arboviruses replicate efficiently in both mosquito vector as well as in its vertebrate host. These viruses thus encounter the innate and adaptive immune responses of vertebrates, as well as the — poorly characterized — innate immune system of insects. We study virus-host interaction in insects and mammals.


Specific interests include:

  • Antiviral RNAi.

RNA interference (RNAi) — a mechanism for gene silencing guided by small interfering RNA (siRNA) — is an important antiviral immune response in the fruitfly Drosophila melanogaster and in mosquitoes. In this pathway viral double-stranded RNA (dsRNA) is recognized as non-self and processed into virus-derived siRNA (vsiRNAs). These vsiRNAs are incorporated into Argonaute-2, the central component of the RISC complex. Argonaute 2 then uses the vsiRNAs to find viral RNAs to induce their degradation. The RNAi pathway thus restricts viral replication at two levels: by cleaving viral dsRNA molecules replication intermediates and by destroying single-stranded viral RNAs.

More recently, we found in collaboration with the Saleh lab (Pasteur Institute) that a related small RNA pathway, the piwi-associated RNA pathway (piRNA), is involved in antiviral defense in mosquitoes. This pathway was previously known to be involved in control of transposable elements in germline tissues, but now seems to also process viral RNA substrates in Aedes mosquitoes. We study how viruses are recognized and targeted by the siRNA and piRNA RNA pathways in flies and mosquitoes.

As a counter-defense to the powerful antiviral RNAi response, viruses have evolved sophisticated mechanisms to suppress or evade it. We have recently identified virus-encoded suppressor proteins in mosquito- and Drosophila viruses. These proteins interfere with different steps of the RNAi pathway. For example, the Nora virus VP1 protein suppresses the catalytic activity of Argonaute-2, underlining the importance of Argonaute 2 in antiviral defense. Several other viral suppressors of RNAi that we recently identified bind dsRNA to interfere with vsiRNA biogenesis and to prevent their incorporation into RISC. We study the mechanism of action of viral RNAi suppressors and their role in virus evolution, host specificity and vector competence.

bronkhorst fly fig 1 aangepast voor website

Schematic representation of the antiviral RNAi pathway. Figure adapted from Bronkhorst et al Fly 2013.

  • Innate antiviral immunity.

Vertebrates depend on a sophisticated network of interferon-based innate responses and adaptive immune responses for antiviral defense. Insects and other non-vertebrates, however, lack these responses, but – like all organisms – frequently encounter viral pathogens. Understanding insect immunity is important from a fundamental perspective, but also central to our understanding of virus transmission by vector mosquitoes. Virus-infected mosquitoes often carry high viral loads, without overt pathology, suggesting that they have efficient mechanisms to tolerate or control infection.

In addition to RNAi, antiviral immunity in insects relies on other, poorly characterized mechanisms. For example, the Jak-Stat pathway and the NF-kB pathways have been implicated in antiviral defense in some infection models, but how viral infection is sensed and the downstream antiviral effector genes remain undefined. Using a combination of transcriptomics and functional genomics in the fly, we wish to identify novel mechanism for antiviral defense and analyze epigenetic regulation of innate immunity.

Newpathwaysppt shade

Drosophila immune pathways. Figure adapted from Merkling et al J Insect Phys 2013

  • Dengue virus-host interactions and antiviral compounds.

Despite the enormous global disease burden and health care costs associated with Dengue virus, no licensed drug or vaccine is available. Hence, there is an urgent need for compounds with anti-DENV activity. Viruses rely on host factors for every step of their replication cycle and these host factors may be promising targets for therapeutic intervention.

We recently screened a library of drug-like small molecules and identified a number of novel inhibitors of DENV replication. We currently study their mechanism of action and hope to identify the cellular target of the identified compounds. This work may yield leads for antiviral drug development as well as provide insight into the viral replication cycle.